Shots:
- Agenus has completed its strategic collaboration with Zydus Lifesciences to accelerate global development and potential commercialization of the BOT+BAL immunotherapy program
- As per the deal, Zydus gave $75M upfront payment to Agenus for US biologics manufacturing facilities, and Agenus is also eligible for Contingent Milestone Payments ~$50M in production-linked milestones. Zydus acquired common stock of Agenus $16M (~2.1M shares), and also receives an exclusive BOT+BAL license for India and Sri Lanka, with Agenus earning a 5% royalty on net sales
- In 2025, BOT+BAL showed a 42% two-year OS and a mOS of 21 mos in 3L or later MSS mCRC patients without active liver metastases, prompting Agenus and CCTG to launch the global P-III trial (BATTMAN), now open for enrollment
Ref: Agenus | Image: Agenus and Zydus Lifesciences | Press Release
Related News: Genethon Signs Worldwide Licensing Agreement with AskBio (Bayer AG) to Advance Gene Therapy for Pompe Disease
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
